Image Place holder

Mihaela Druta, MD


Specialty: Medical Oncology
Program: Sarcoma

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: GIST (Gastrointestinal Stromal Tumor) , Osteosarcoma , Sarcoma

Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia.  She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center.  Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center. Dr. Druta's clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients.  Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.

Education & Training

Board Certification:

  • Internal Medicine
  • Internal Medicine

Fellowship:

  • H. Lee Moffitt Cancer Center - Hematology and Medical Oncology
  • MD Anderson Cancer Center - Sarcoma Medical Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of Medicine and Pharmacy Carol Davilla - MD
Participating Trials

CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 19504
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Intervention: Avapritinib; BAY 73-4506 (Regorafenib); BLU-285 (Avapritinib); Not Applicable; Regorafenib (Stivarga)
Open

CLINICAL TRIAL 19776
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3021
Open

CLINICAL TRIAL 19707
Phase 1 Dose Escalation, Multi-Tumor Study To Assess The Safety, Tolerability And Antitumor Activity Of Genetically Engineered Mage-A4c1032t In Hla-A2+ Subjects With Mage-A4 Positive Tumors
Condition: Sarcoma
Intervention: MAGE-A4; MESNA; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18613
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Condition: Sarcoma
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); gemcitabine
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 19365
Phase I Trial of the LSD1 inhibitor SP-2577 in Patients with Relapsed or Refractory Ewing Sarcoma
Condition: Sarcoma
Intervention: SP-2577
Open

CLINICAL TRIAL 19878
A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma
Condition: Sarcoma
Intervention: Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Pham V, Henderson-Jackson E, Doepker MP, Caracciolo JT, Gonzalez RJ, Druta M, Ding Y, Bui MM. Practical Issues for Retroperitoneal Sarcoma. Cancer Control. 2016 Jul;23(3):249-264. Pubmedid: 27556665.
  • Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul;112(1):103-106. Pubmedid: 26179670.
  • Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?. Geriatr Oncol. 2014 Jan;5(1):40-48. Pubmedid: 24484717. Pmcid: PMC4527303.
  • Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
  • Jacobsen PB, Shibata D, Siegel EM, Druta M, Lee JH, Marshburn J, Davenport L, Cruse H, Levine R, Gondi A, Brown R, Malafa M. Measuring quality of care in the treatment of colorectal cancer: the moffitt quality practice initiative. J Oncol Pract. 2007 Mar;3(2):60-65. Pubmedid: 20859375. Pmcid: PMC2793747.